Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 452

1.

Use of illicit amphetamines is associated with long-lasting changes in hand circuitry and control.

Pearson-Dennett V, Faulkner PL, Collie B, Wilcox RA, Vogel AP, Thewlis D, Esterman A, McDonnell MN, Gandevia SC, White JM, Todd G.

Clin Neurophysiol. 2019 Feb 26;130(5):655-665. doi: 10.1016/j.clinph.2019.02.005. [Epub ahead of print]

PMID:
30870801
2.

Speech treatment improves dysarthria in multisystemic ataxia: a rater-blinded, controlled pilot-study in ARSACS.

Vogel AP, Stoll LH, Oettinger A, Rommel N, Kraus EM, Timmann D, Scott D, Atay C, Storey E, Schöls L, Synofzik M.

J Neurol. 2019 Mar 6. doi: 10.1007/s00415-019-09258-4. [Epub ahead of print]

PMID:
30840144
3.

The Vitamins in Psychosis Study: A Randomized, Double-Blind, Placebo-Controlled Trial of the Effects of Vitamins B12, B6, and Folic Acid on Symptoms and Neurocognition in First-Episode Psychosis.

Allott K, McGorry PD, Yuen HP, Firth J, Proffitt TM, Berger G, Maruff P, O'Regan MK, Papas A, Stephens TCB, O'Donnell CP.

Biol Psychiatry. 2019 Jan 9. pii: S0006-3223(19)30001-0. doi: 10.1016/j.biopsych.2018.12.018. [Epub ahead of print]

PMID:
30771856
4.

Klotho allele status is not associated with Aβ and APOE ε4-related cognitive decline in preclinical Alzheimer's disease.

Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Lim YY, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM.

Neurobiol Aging. 2019 Apr;76:162-165. doi: 10.1016/j.neurobiolaging.2018.12.014. Epub 2019 Jan 6.

PMID:
30716541
5.

A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimer's Disease.

Porter T, Burnham SC, Savage G, Lim YY, Maruff P, Milicic L, Peretti M, Ames D, Masters CL, Martins RN, Rainey-Smith S, Rowe CC, Salvado O, Taddei K, Groth D, Verdile G, Villemagne VL, Laws SM.

Front Aging Neurosci. 2018 Dec 19;10:423. doi: 10.3389/fnagi.2018.00423. eCollection 2018.

6.

Monitoring cognitive change in multiple sclerosis using a computerized cognitive battery.

De Meijer L, Merlo D, Skibina O, Grobbee EJ, Gale J, Haartsen J, Maruff P, Darby D, Butzkueven H, Van der Walt A.

Mult Scler J Exp Transl Clin. 2018 Dec 10;4(4):2055217318815513. doi: 10.1177/2055217318815513. eCollection 2018 Oct-Dec.

7.

Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia.

Slot RER, Sikkes SAM, Berkhof J, Brodaty H, Buckley R, Cavedo E, Dardiotis E, Guillo-Benarous F, Hampel H, Kochan NA, Lista S, Luck T, Maruff P, Molinuevo JL, Kornhuber J, Reisberg B, Riedel-Heller SG, Risacher SL, Roehr S, Sachdev PS, Scarmeas N, Scheltens P, Shulman MB, Saykin AJ, Verfaillie SCJ, Visser PJ, Vos SJB, Wagner M, Wolfsgruber S, Jessen F; Alzheimer's Disease Neuroimaging Initiative; DESCRIPA working group; INSIGHT-preAD study group; SCD-I working group, van der Flier WM.

Alzheimers Dement. 2019 Mar;15(3):465-476. doi: 10.1016/j.jalz.2018.10.003. Epub 2018 Dec 13.

8.

Reduced professional efficacy is associated with a blunted salivary alpha-amylase awakening response.

Landolt K, Maruff P, Horan B, Kingsley M, Kinsella G, O'Halloran PD, Hale MW, Wright BJ.

Physiol Behav. 2019 Feb 1;199:292-299. doi: 10.1016/j.physbeh.2018.11.038. Epub 2018 Nov 29.

PMID:
30503848
9.

Necessity of technicians for computerized neuropsychological assessment devices in multiple sclerosis.

Wojcik CM, Rao SM, Schembri AJ, Drake AS, Maruff P, Schindler D, Alberts J, Yasin F, Pol J, Weinstock-Guttman B, Benedict RH.

Mult Scler. 2018 Nov 22:1352458518813287. doi: 10.1177/1352458518813287. [Epub ahead of print]

PMID:
30465463
10.

A Review: Mealtime Difficulties following Frontotemporal Lobar Degeneration.

Lewis C, Walterfang M, Velakoulis D, Vogel AP.

Dement Geriatr Cogn Disord. 2018;46(5-6):285-297. doi: 10.1159/000494210. Epub 2018 Nov 13. Review.

11.

Incidence of emergency department presentations for traumatic brain injury in Indigenous and non-Indigenous residents aged 15-64 over the 9-year period 2007-2015 in North Queensland, Australia.

Esterman A, Thompson F, Fitts M, Gilroy J, Fleming J, Maruff P, Clough A, Bohanna I.

Inj Epidemiol. 2018 Nov 12;5(1):40. doi: 10.1186/s40621-018-0172-9.

12.

Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.

Porter T, Burnham SC, Milicic L, Savage G, Maruff P, Lim YY, Li QX, Ames D, Masters CL, Rainey-Smith S, Rowe CC, Salvado O, Groth D, Verdile G, Villemagne VL, Laws SM; AIBL Research Group.

J Alzheimers Dis. 2018;66(3):1193-1211. doi: 10.3233/JAD-180713.

PMID:
30412495
13.

Unsupervised online neuropsychological test performance for individuals with mild cognitive impairment and dementia: Results from the Brain Health Registry.

Mackin RS, Insel PS, Truran D, Finley S, Flenniken D, Nosheny R, Ulbright A, Comacho M, Bickford D, Harel B, Maruff P, Weiner MW.

Alzheimers Dement (Amst). 2018 Jun 21;10:573-582. doi: 10.1016/j.dadm.2018.05.005. eCollection 2018.

14.

Online study partner-reported cognitive decline in the Brain Health Registry.

Nosheny RL, Camacho MR, Insel PS, Flenniken D, Fockler J, Truran D, Finley S, Ulbricht A, Maruff P, Yaffe K, Mackin RS, Weiner MW.

Alzheimers Dement (N Y). 2018 Oct 15;4:565-574. doi: 10.1016/j.trci.2018.09.008. eCollection 2018.

15.

Mediterranean diet adherence and rate of cerebral Aβ-amyloid accumulation: Data from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing.

Rainey-Smith SR, Gu Y, Gardener SL, Doecke JD, Villemagne VL, Brown BM, Taddei K, Laws SM, Sohrabi HR, Weinborn M, Ames D, Fowler C, Macaulay SL, Maruff P, Masters CL, Salvado O, Rowe CC, Scarmeas N, Martins RN.

Transl Psychiatry. 2018 Oct 30;8(1):238. doi: 10.1038/s41398-018-0293-5.

16.

What speech can tell us: A systematic review of dysarthria characteristics in Multiple Sclerosis.

Noffs G, Perera T, Kolbe SC, Shanahan CJ, Boonstra FMC, Evans A, Butzkueven H, van der Walt A, Vogel AP.

Autoimmun Rev. 2018 Dec;17(12):1202-1209. doi: 10.1016/j.autrev.2018.06.010. Epub 2018 Oct 11.

PMID:
30316992
17.

Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.

Scheltens P, Hallikainen M, Grimmer T, Duning T, Gouw AA, Teunissen CE, Wink AM, Maruff P, Harrison J, van Baal CM, Bruins S, Lues I, Prins ND.

Alzheimers Res Ther. 2018 Oct 12;10(1):107. doi: 10.1186/s13195-018-0431-6.

18.

Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.

Robertson K, Maruff P, Ross LL, Wohl D, Small CB, Edelstein H, Shaefer MS.

J Neurovirol. 2019 Feb;25(1):22-31. doi: 10.1007/s13365-018-0680-y. Epub 2018 Oct 8.

PMID:
30298202
19.

Superior Memory Reduces 8-year Risk of Mild Cognitive Impairment and Dementia But Not Amyloid β-Associated Cognitive Decline in Older Adults.

Dang C, Harrington KD, Lim YY, Ames D, Hassenstab J, Laws SM, Yassi N, Hickey M, Rainey-Smith SR, Robertson J, Rowe CC, Sohrabi HR, Salvado O, Weinborn M, Villemagne VL, Masters CL, Maruff P; AIBL Research Group.

Arch Clin Neuropsychol. 2018 Oct 1. doi: 10.1093/arclin/acy078. [Epub ahead of print]

PMID:
30272115
20.

Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease.

Arora S, Visanji NP, Mestre TA, Tsanas A, AlDakheel A, Connolly BS, Gasca-Salas C, Kern DS, Jain J, Slow EJ, Faust-Socher A, Lang AE, Little MA, Marras C.

J Parkinsons Dis. 2018;8(4):503-510. doi: 10.3233/JPD-181389.

PMID:
30248062

Supplemental Content

Loading ...
Support Center